Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220982 | 1.00 | MAPT (0.38) | MAPTPKMCYP19A1ERN1ALDH1A1 | |
| SCHEMBL1221344 | 0.85 | MAPT (0.39) | MAPTPKMPOLBTSHRMAPK1 | |
| SCHEMBL14964659 | 0.83 | CHRNB2 (0.42) | MAPTPKMCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29108682 | 0.82 | ALDH1A1 (0.42) | MAPTCYP19A1ALDH1A1POLBTSHR | |
| SCHEMBL12884003 | 0.81 | CPB1 (0.38) | MAPTPKMCYP19A1ERN1ALDH1A1 | |
| SCHEMBL12895760 | 0.81 | CPB1 (0.38) | MAPTPKMCYP19A1ERN1ALDH1A1 | |
| SCHEMBL11401788 | 0.81 | MAPT (0.37) | MAPTPKMALDH1A1POLBTSHR | |
| SCHEMBL27294855 | 0.78 | CYP19A1 (0.35) | MAPTCYP19A1ERN1ALDH1A1KDM4E | |
| SCHEMBL2381816 | 0.75 | TSHR (0.35) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL31153901 | 0.75 | CHRNB2 (0.39) | MAPTPKMTSHRCHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1699797-B1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2058314-A1 | Pyrrolotriazine compounds as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-1863792-B1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1863792-A1 | ATP COMPETITIVE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7141571-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006104971-A1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1699797-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| WO-2005066176-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | MAPT 2432/4885PKM 1164/4885CYP19A1 1307/4885 |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | ERBB2, ERBB4, EGFR | MAPT 3946/4885PKM 2061/4885CYP19A1 1917/4885 |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | MAPT 2432/4885PKM 1164/4885CYP19A1 1307/4885 |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | ERBB2, ERBB4, ERBB3 | MAPT 2432/4885PKM 1164/4885CYP19A1 1307/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | MAPT 2432/4885PKM 1164/4885CYP19A1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.